Most Read Articles
Rachel Soon, 16 Aug 2019

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

3 days ago
Cardiac biomarkers are useful for identifying community-acquired pneumonia (CAP) patients with an elevated risk of early and long-term cardiovascular (CV) events, according to a study.
23 hours ago
Tofogliflozin is safe and effective for elderly patients with type 2 diabetes mellitus (T2DM), regardless of insulin and oral antidiabetic drugs, reports a new Japan study.
5 days ago
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.

Rupatadine safe, effective for chronic spontaneous urticaria, dermatitis, pruritus

12 Jul 2019

Rupatadine for the management of patients with chronic spontaneous urticaria, dermatitis and pruritus is safe in the short and long term, according to a recent Japan study.

Researchers conducted a multicentre, open-label clinical trial including 206 participants who were given the study medication. Efficacy was assessed primarily through the change in total pruritus score (TPS) from baseline to week 2. Rupatadine was administered initially at 10 mg once daily, though updosing to 20 mg was allowed starting week 3.

Of the participants, majority had eczema or dermatitis (n=132); 58 had pruritus and 16 had chronic spontaneous urticaria.

The primary efficacy analysis revealed a significant 2-week change in TPS (–1.241, 95 percent CI, –1.450 to –1.033; p<0.001). This remained significant even when restricting analysis to adolescents (mean change, –0.745; p=0.008) or adults (mean change, –1.304; p<0.001).

Disaggregating according to disease type likewise did not meaningfully change the results. Mean changes in disease score for those with eczema or dermatitis, pruritus and chronic spontaneous urticaria were –1.071, –1.183 and –2.971, respectively, and all of which were significant (p<0.001).

In terms of safety, the incidence rate of adverse events from baseline to week 2 was 18.9 percent. This climbed to 38.6 percent between weeks 3 and 12, and further to 67.8 percent between weeks 13 and 52. Adverse drug reactions showed an opposite, downward trend, starting at 9.7 percent between weeks 1 and 2 and dropping to 1.7 percent between weeks 13 and 52.

 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 16 Aug 2019

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

3 days ago
Cardiac biomarkers are useful for identifying community-acquired pneumonia (CAP) patients with an elevated risk of early and long-term cardiovascular (CV) events, according to a study.
23 hours ago
Tofogliflozin is safe and effective for elderly patients with type 2 diabetes mellitus (T2DM), regardless of insulin and oral antidiabetic drugs, reports a new Japan study.
5 days ago
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.